← Leaderboards
Carmelo Nucera
Beth Israel Deaconess Medical Center
$4,177,998
Attributed
$4,177,998
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $400.3K · FY2012–24$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,177,998 · 3
By mechanism
R01$3,770,786 · 2
R21$407,212 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Bjorn R Olsen$23,352,119
- Harold Fisher Dvorak$13,877,917
- Frank W Sellke$18,106,428
- David McDermott$9,360,637
- Donald R Senger$6,635,477
Others in their field
Top investigators on “Thyroid Gland”
- Keri Hammel · The Emmes Company, Llc$17,992,237
- Stanley R Hamilton · Johns Hopkins University$17,360,724
- James A Fagin · Sloan-Kettering Inst Can Research$15,918,667
- Ignacio I. Wistuba · Ut Southwestern Medical Center$15,303,923
- Keri, Hammel · The Emmes Company, Llc$11,064,901
- Darrell N. Kotton · Boston University Medical Campus$10,211,667
Research focus
Thyroid GlandDrug ResistanceResistanceSignal TransductionTumorExtracellular Matrix ProteinsNeoplasm MetastasisRecurrencePathway InteractionsSamplingLinkClinical TrialsCancer CellGenesMouse ModelIn VitroCellsMutationEarly DiagnosisCoculture TechniquesMetabolismPapillary Thyroid CarcinomaCombined Modality TherapyPericytes
Grant awards (12)
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma$380,298
R01 · FY2024 · CA · contact PI
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma$392,306
R01 · FY2023 · CA · contact PI
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma$392,306
R01 · FY2022 · CA · contact PI
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma$400,313
R01 · FY2021 · CA · contact PI
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinoma$400,313
R01 · FY2020 · CA · contact PI
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression$361,050
R01 · FY2018 · CA · contact PI
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression$361,050
R01 · FY2017 · CA · contact PI
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression$361,050
R01 · FY2016 · CA · contact PI
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression$361,050
R01 · FY2015 · CA · contact PI
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression$361,050
R01 · FY2014 · CA · contact PI
Metastatic protein network in BRAFV600E positive human thyroid cancers$142,297
R21 · FY2013 · CA · contact PI
Metastatic protein network in BRAFV600E positive human thyroid cancers$264,915
R21 · FY2012 · CA · contact PI